MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$15,474K
EPS
-$0.4
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development
12,702
11,648
12,687*
10,992
General and administrative
4,726
5,256
4,717*
3,940
Total operating expenses
17,428
16,904
17,404
14,932
Loss from operations
-17,428
-16,904
-17,404*
-14,932
Interest income
2,342
2,505
892*
-
Change in fair value of warrant liability
-
-
0*
-
Other expense, net
-68
-57
-41*
-
Total other income, net
2,274
2,448
851*
2,410
Net loss
-15,154
-14,456
-16,553*
-12,792
Unrealized loss (gain) on marketable securities
-320
-513
-165*
118
Comprehensive loss
-15,474
-14,969
-16,718
-12,674
Basic EPS
-0.4
-0.39
-0.613
-0.45
Diluted EPS
-0.4
-0.39
-0.604
-
Basic Average Shares
37,467,840
37,339,026
27,286,162
28,115,548
Diluted Average Shares
37,467,840
37,339,026
27,700,855
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive loss
-$15,474K
Interest income
$2,342K
(15.43%↑ Y/Y)
Net loss
-$15,154K
(5.52%↑ Y/Y)
Unrealized loss (gain) on
marketable securities
-$320K
Total other income,
net
$2,274K
Other expense, net
-$68K
Loss from operations
-$17,428K
Total operating
expenses
$17,428K
Research and development
$12,702K
General and
administrative
$4,726K
(23.10%↑ Y/Y)
Buy us a coffee
Contineum Therapeutics, Inc. (CTNM)
Contineum Therapeutics, Inc. (CTNM)